NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft
Portfolio Pulse from Benzinga Newsdesk
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) have announced an agreement where NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic Tissue Allograft. The product is intended for use as a protective covering during the repair of ocular surfaces.
September 11, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioStem Technologies has entered into an agreement with NovaBay Pharmaceuticals for the commercialization of its Amniotic Tissue Allograft.
The agreement with NovaBay could lead to increased revenues for BioStem if the product is successful. This is directly relevant to BioStem and could be important for investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
NovaBay Pharmaceuticals has been granted the right to commercialize BioStem Technologies' Amniotic Tissue Allograft, potentially opening a new revenue stream.
The agreement allows NovaBay to commercialize BioStem's product, which could lead to increased revenues if the product is successful. This is directly relevant to NovaBay and could be important for investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100